On the public citation graph

Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study

0 signed · 171 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archneur.60.8.1059openalex-snapshot
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
inferredcites →https://doi.org/10.1001/archneurol.2011.1060openalex-snapshot
Prospective Study of Statin Use and Risk of Parkinson Disease
inferredcites →https://doi.org/10.1001/jama.2013.284657openalex-snapshot
More Than a Billion People Taking Statins?
inferredcites →https://doi.org/10.1002/mds.21290openalex-snapshot
Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease
inferredcites →https://doi.org/10.1002/mds.22013openalex-snapshot
Low LDL cholesterol and increased risk of Parkinson's disease: Prospective results from Honolulu‐Asia Aging Study
inferredcites →https://doi.org/10.1002/mds.23102openalex-snapshot
Statin use and Parkinson's disease in Denmark
inferredcites →https://doi.org/10.1016/j.expneurol.2009.11.015openalex-snapshot
Lovastatin ameliorates α-synuclein accumulation and oxidation in transgenic mouse models of α-synucleinopathies
inferredcites →https://doi.org/10.1016/j.jns.2010.03.002openalex-snapshot
Case–control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan
inferredcites →https://doi.org/10.1016/j.jocn.2008.01.016openalex-snapshot
Statin use and the risk of Parkinson disease: a nested case control study
inferredcites →https://doi.org/10.1016/j.plipres.2011.06.002openalex-snapshot
Cholesterol metabolism in neurons and astrocytes
inferredcites →https://doi.org/10.1016/s0014-5793(98)01712-8openalex-snapshot
Determinants of plasma coenzyme Q10 in humans
inferredcites →https://doi.org/10.1016/s0021-9150(98)00070-7openalex-snapshot
Lack of association between ferritin level and measures of LDL oxidation: The ARIC Study1Paper presented at the 4th International Conference on Preventive Cardiology, Montréal, Canada, June 29–July 3, 1997.1
inferredcites →https://doi.org/10.1023/b:jobb.0000041772.74810.92openalex-snapshot
Mitochondrial Dysfunction and Oxidative Damage in Alzheimer's and Parkinson's Diseases and Coenzyme Q10 as a Potential Treatment
inferredcites →https://doi.org/10.1056/nejmoa1315665openalex-snapshot
Application of New Cholesterol Guidelines to a Population-Based Sample
inferredcites →https://doi.org/10.1093/aje/kwj283openalex-snapshot
Serum Cholesterol Levels and the Risk of Parkinson's Disease
inferredcites →https://doi.org/10.1093/aje/kwj323openalex-snapshot
Coffee and Sweetened Beverage Consumption and the Risk of Type 2 Diabetes Mellitus: The Atherosclerosis Risk in Communities Study
inferredcites →https://doi.org/10.1111/j.1471-4159.2008.05254.xopenalex-snapshot
Statins reduce neuronal α‐synuclein aggregation in in vitro models of Parkinson’s disease
inferredcites →https://doi.org/10.1136/bmj.c2197openalex-snapshot
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database
inferredcites →https://doi.org/10.1161/01.atv.14.7.1098openalex-snapshot
Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study.
inferredcites →https://doi.org/10.1161/01.str.0000217384.03237.9copenalex-snapshot
Reduced Risk Factors for Vascular Disorders in Parkinson Disease Patients
inferredcites →https://doi.org/10.1186/1741-7015-5-20openalex-snapshot
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
inferredcites →https://doi.org/10.1212/01.wnl.0000286942.14552.51openalex-snapshot
Statin use and the risk of Parkinson disease
inferredcites →https://doi.org/10.1212/01.wnl.0000312511.62699.a8openalex-snapshot
Total cholesterol and the risk of Parkinson disease
inferredcites →https://doi.org/10.1212/wnl.0b013e31829d873copenalex-snapshot
Discontinuation of statin therapy associates with Parkinson disease
inferredcites →https://doi.org/10.1212/wnl.0b013e31829d87bbopenalex-snapshot
Holding on to statins in Parkinson disease
inferredcites →https://doi.org/10.1289/ehp.1002839openalex-snapshot
Rotenone, Paraquat, and Parkinson’s Disease
inferredcites →https://doi.org/10.1289/ehp.1306967openalex-snapshot
Research on the Premotor Symptoms of Parkinson’s Disease: Clinical and Etiological Implications
inferredcites →https://doi.org/10.1371/journal.pone.0020945openalex-snapshot
Simvastatin Prevents Dopaminergic Neurodegeneration in Experimental Parkinsonian Models: The Association with Anti-Inflammatory Responses
inferredcites →https://doi.org/10.2165/00002018-200831050-00004openalex-snapshot
Use of Statins and the Risk of Parkinson???s Disease
inferredcites →https://doi.org/10.2165/0129784-200808060-00004openalex-snapshot
Statin Adverse Effects

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4754860openalex-extracted
Sexual Dimorphism on the Role of Lipid and Apolipoprotein Traits in the Risk of Parkinson's Disease
inferred← citeshttps://doi.org/10.1001/jama.2017.19170openalex-snapshot
Risks of Statins for Lower-Risk Individuals
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.12820openalex-snapshot
A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes
inferred← citeshttps://doi.org/10.1002/ana.24751openalex-snapshot
Statin therapy prevents the onset of Parkinson disease in patients with diabetes
inferred← citeshttps://doi.org/10.1002/ana.25614openalex-snapshot
Peripheral immune biomarkers and neurodegenerative diseases: A prospective cohort study with 20 years of follow‐up
inferred← citeshttps://doi.org/10.1002/ana.26670openalex-snapshot
A Comparison Between Early Presentation of Dementia with Lewy Bodies, Alzheimer's Disease, and Parkinson's Disease: Evidence from Routine Primary Care and UK Biobank Data
inferred← citeshttps://doi.org/10.1002/mco2.476openalex-snapshot
Cholesterol metabolism: physiological regulation and diseases
inferred← citeshttps://doi.org/10.1002/mds.26452openalex-snapshot
Plasma fasting cholesterol profiles and age at onset in P arkinson's disease
inferred← citeshttps://doi.org/10.1002/mds.26573openalex-snapshot
S erum 25‐hydroxyvitamin D concentrations in Mid ‐adulthood and P arkinson's disease risk
inferred← citeshttps://doi.org/10.1002/mds.27006openalex-snapshot
Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database
inferred← citeshttps://doi.org/10.1002/mds.27053openalex-snapshot
Linking statins and lipids in Parkinson's disease
inferred← citeshttps://doi.org/10.1002/mds.27413openalex-snapshot
Higher serum cholesterol and decreased Parkinson's disease risk: A statin‐free cohort study
inferred← citeshttps://doi.org/10.1002/mds.27681openalex-snapshot
Association of statin use with Parkinson's disease: Dose–response relationship
inferred← citeshttps://doi.org/10.1002/mds.27836openalex-snapshot
Understanding the Links Between Cardiovascular Disease and Parkinson's Disease
inferred← citeshttps://doi.org/10.1002/mds.28396openalex-snapshot
The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease
inferred← citeshttps://doi.org/10.1002/mds.29349openalex-snapshot
Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study
inferred← citeshttps://doi.org/10.1002/mds.30149openalex-snapshot
Self‐Reported Motor and Nonmotor Symptoms, Prodromal Parkinson's Disease Probability, and Incident Parkinson's Disease in US Farmers
inferred← citeshttps://doi.org/10.1002/pds.4079openalex-snapshot
Confounding of the association between statins and Parkinson disease: systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1007/s00415-017-8403-5openalex-snapshot
Does apolipoprotein A1 predict microstructural changes in subgenual cingulum in early Parkinson?
inferred← citeshttps://doi.org/10.1007/s00702-015-1443-zopenalex-snapshot
Parkinson’s disease between internal medicine and neurology
inferred← citeshttps://doi.org/10.1007/s00702-021-02437-6openalex-snapshot
Cognition, motor symptoms, and glycolipid metabolism in Parkinson’s disease with depressive symptoms
inferred← citeshttps://doi.org/10.1007/s10072-023-06926-2openalex-snapshot
The potential role of cholesterol in Parkinson’s disease neuropathology: perpetrator or victim
inferred← citeshttps://doi.org/10.1007/s10072-026-09070-9openalex-snapshot
When bad turns good: a systematic review on cholesterol and LDL in longitudinal patient cohorts with Parkinson’s disease
inferred← citeshttps://doi.org/10.1007/s10654-021-00730-yopenalex-snapshot
Heart rate, intelligence in adolescence, and Parkinson’s disease later in life
inferred← citeshttps://doi.org/10.1007/s11011-017-0021-5openalex-snapshot
The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration
inferred← citeshttps://doi.org/10.1007/s12017-016-8435-5openalex-snapshot
Mutant A53T α-Synuclein Improves Rotarod Performance Before Motor Deficits and Affects Metabolic Pathways
inferred← citeshttps://doi.org/10.1007/s12035-020-02232-6openalex-snapshot
Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets
inferred← citeshttps://doi.org/10.1007/s12035-023-03798-7openalex-snapshot
Potential Use of the Cholesterol Transfer Inhibitor U18666A as a Potent Research Tool for the Study of Cholesterol Mechanisms in Neurodegenerative Disorders
inferred← citeshttps://doi.org/10.1016/b978-0-12-813792-5.00006-9openalex-snapshot
Statins: Rationale, Mode of Action, and Side Effects
inferred← citeshttps://doi.org/10.1016/bs.irn.2026.08.001openalex-snapshot
Progress in blood-derived biomarkers for Parkinson’s disease
inferred← citeshttps://doi.org/10.1016/j.amjcard.2018.09.041openalex-snapshot
Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment
inferred← citeshttps://doi.org/10.1016/j.amjcard.2020.09.021openalex-snapshot
Cardiovascular Risk Among Patients ≥65 Years of Age with Parkinson's Disease (From the National Inpatient Sample)
inferred← citeshttps://doi.org/10.1016/j.arr.2022.101618openalex-snapshot
Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson’s disease
inferred← citeshttps://doi.org/10.1016/j.atherosclerosissup.2016.10.003openalex-snapshot
A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence
inferred← citeshttps://doi.org/10.1016/j.bbr.2016.04.046openalex-snapshot
Statin use and risk of Parkinson’s disease: A meta-analysis
inferred← citeshttps://doi.org/10.1016/j.biopha.2017.04.038openalex-snapshot
Current insights into pathogenesis of Parkinson’s disease: Approach to mevalonate pathway and protective role of statins
inferred← citeshttps://doi.org/10.1016/j.celrep.2016.06.013openalex-snapshot
Protein Prenylation Constitutes an Endogenous Brake on Axonal Growth
inferred← citeshttps://doi.org/10.1016/j.crphar.2020.100012openalex-snapshot
Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal
inferred← citeshttps://doi.org/10.1016/j.dscb.2022.100048openalex-snapshot
Shared polygenic risk and causal inferences in Parkinson's disease
inferred← citeshttps://doi.org/10.1016/j.ejcb.2017.01.002openalex-snapshot
Impact of high cholesterol in a Parkinson’s disease model: Prevention of lysosomal leakage versus stimulation of α-synuclein aggregation
inferred← citeshttps://doi.org/10.1016/j.ejphar.2022.174800openalex-snapshot
Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
inferred← citeshttps://doi.org/10.1016/j.lpm.2017.01.001openalex-snapshot
Epidemiology, environmental risk factors and genetics of Parkinson's disease
inferred← citeshttps://doi.org/10.1016/j.mad.2024.111942openalex-snapshot
Understanding the (epi)genetic dysregulation in Parkinson's disease through an integrative brain competitive endogenous RNA network
inferred← citeshttps://doi.org/10.1016/j.nbd.2019.104671openalex-snapshot
Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?
inferred← citeshttps://doi.org/10.1016/j.neuint.2015.07.025openalex-snapshot
Cholesterol – A putative endogenous contributor towards Parkinson's disease
inferred← citeshttps://doi.org/10.1016/j.neuint.2017.01.021openalex-snapshot
Hypercholesterolemia causes psychomotor abnormalities in mice and alterations in cortico-striatal biogenic amine neurotransmitters: Relevance to Parkinson's disease
inferred← citeshttps://doi.org/10.1016/j.neurol.2015.09.012openalex-snapshot
Epidemiology of Parkinson's disease
inferred← citeshttps://doi.org/10.1016/j.neurol.2016.07.001openalex-snapshot
Prodromal symptoms of Parkinson's disease: Implications for epidemiological studies of disease etiology
inferred← citeshttps://doi.org/10.1016/j.neuropharm.2018.01.039openalex-snapshot
Membrane cholesterol removal and replenishment affect rat and monkey brain monoamine transporters
inferred← citeshttps://doi.org/10.1016/j.parkreldis.2018.09.011openalex-snapshot
The importance of preclinical diagnostics in Parkinson disease
inferred← citeshttps://doi.org/10.1016/j.parkreldis.2021.02.007openalex-snapshot
Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study
inferred← citeshttps://doi.org/10.1016/j.parkreldis.2021.09.021openalex-snapshot
Statin use and pneumonia risk in Parkinson's disease
inferred← citeshttps://doi.org/10.1016/j.parkreldis.2022.02.011openalex-snapshot
Association between statin use and Parkinson's disease in Korean patients with hyperlipidemia
inferred← citeshttps://doi.org/10.1016/j.parkreldis.2023.105881openalex-snapshot
Association between lipid levels and the risk of Parkinson's disease in individuals with diabetes mellitus: A nationwide population-based cohort study
inferred← citeshttps://doi.org/10.1016/j.parkreldis.2024.107026openalex-snapshot
Update: Protective and risk factors for Parkinson disease
inferred← citeshttps://doi.org/10.1016/j.parkreldis.2026.108323openalex-snapshot
Serum metabolic markers for α-synucleinopathies conversion in isolated REM sleep behavior disorder: a prospective cohort study
inferred← citeshttps://doi.org/10.1016/j.pnpbp.2015.11.013openalex-snapshot
Statins and the brain: New perspective for old drugs
inferred← citeshttps://doi.org/10.1016/s1474-4422(16)30230-7openalex-snapshot
The epidemiology of Parkinson's disease: risk factors and prevention
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6c01274openalex-snapshot
Enzyme−Targeted Therapeutics for Neurological Disorders
inferred← citeshttps://doi.org/10.1021/acschemneuro.8b00520openalex-snapshot
Advances in the Research of Risk Factors and Prodromal Biomarkers of Parkinson’s Disease
inferred← citeshttps://doi.org/10.1021/jacsau.5c01563openalex-snapshot
Lipid Composition Drastically Alters Tau–Membrane Interaction: Implications for Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1038/nrneurol.2016.56openalex-snapshot
Insect screens for PD therapies — keep the flies in
inferred← citeshttps://doi.org/10.1038/s41531-017-0015-3openalex-snapshot
Integrated molecular landscape of Parkinson’s disease
inferred← citeshttps://doi.org/10.1038/s41531-024-00713-2openalex-snapshot
Metabolic profiling reveals circulating biomarkers associated with incident and prevalent Parkinson’s disease
inferred← citeshttps://doi.org/10.1038/s41531-025-01003-1openalex-snapshot
Lower prevalence of metabolic syndrome and its components in the prediagnostic phase of Parkinson’s disease
inferred← citeshttps://doi.org/10.1038/s41531-025-01007-xopenalex-snapshot
Prediction of all-cause mortality in Parkinson’s disease with explainable artificial intelligence using administrative healthcare data
inferred← citeshttps://doi.org/10.1038/s41531-025-01023-xopenalex-snapshot
Lipid profiling of Parkinson’s disease brain highlights disruption in Lysophosphatidylcholines, and triacylglycerol metabolism
inferred← citeshttps://doi.org/10.1038/s41598-017-12858-7openalex-snapshot
Age-related neurodegenerative disease associated pathways identified in retinal and vitreous proteome from human glaucoma eyes
inferred← citeshttps://doi.org/10.1038/s41598-020-66319-9openalex-snapshot
Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease
inferred← citeshttps://doi.org/10.1038/s41598-022-25180-8openalex-snapshot
Association between serum lipid levels over time and risk of Parkinson’s disease
inferred← citeshttps://doi.org/10.1080/00207454.2018.1492574openalex-snapshot
Uric acid level may not be reduced in essential tremor
inferred← citeshttps://doi.org/10.1080/14728222.2018.1517156openalex-snapshot
Chaperone-mediated autophagy as a therapeutic target for Parkinson disease
inferred← citeshttps://doi.org/10.1080/17512433.2018.1519391openalex-snapshot
LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature
inferred← citeshttps://doi.org/10.1080/21678421.2018.1511731openalex-snapshot
Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly
inferred← citeshttps://doi.org/10.1093/brain/awab292openalex-snapshot
Effects of statins on dopamine loss and prognosis in Parkinson’s disease
inferred← citeshttps://doi.org/10.1093/braincomms/fcae195openalex-snapshot
Statin use and risk of Parkinson’s disease among older adults in Japan: a nested case–control study using the Longevity Improvement and Fair Evidence study
inferred← citeshttps://doi.org/10.1097/md.0000000000014852openalex-snapshot
Effect of statins on Parkinson's disease
inferred← citeshttps://doi.org/10.1099/jgv.0.000876openalex-snapshot
Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice
inferred← citeshttps://doi.org/10.1101/2024.12.06.24318632openalex-snapshot
Association of Vascular Risk Factors with the Risk of Parkinson’s Disease among Stroke Survivors—A Nationwide Population-Based Study
inferred← citeshttps://doi.org/10.1101/2025.07.30.25332433openalex-snapshot
Plasma proteomics in the prediagnostic phase of Parkinson’s disease: a multi-cohort study of 74,000 participants
inferred← citeshttps://doi.org/10.1101/253690openalex-snapshot
Risk factors associated with Parkinson’s disease: An 11-year population-based South Korean study
inferred← citeshttps://doi.org/10.1101/608216openalex-snapshot
How delayed treatment benefits and harms would impact the optimal timing of statin initiation for cardiovascular primary prevention
inferred← citeshttps://doi.org/10.1111/bcp.16035openalex-snapshot
Statin use and the risk of Parkinson's disease in persons with diabetes: A nested case–control study
inferred← citeshttps://doi.org/10.1111/cns.14888openalex-snapshot
Determining the role of statins in Parkinson's disease risk reduction and disease modification: A comprehensive meta‐analysis of 4 million participants' data
inferred← citeshttps://doi.org/10.1111/ejn.15566openalex-snapshot
Bioactive lipids and their metabolism: New therapeutic opportunities for Parkinson's disease
inferred← citeshttps://doi.org/10.1111/ene.15592openalex-snapshot
Association of cholesterol level with dopamine loss and motor deficits in Parkinson disease: A cross‐sectional study
inferred← citeshttps://doi.org/10.1124/pr.115.011502openalex-snapshot
Mitochondrial Quality Control as a Therapeutic Target
inferred← citeshttps://doi.org/10.1136/bmj.j1648openalex-snapshot
Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
inferred← citeshttps://doi.org/10.1145/3097983.3098065openalex-snapshot
Prognosis and Diagnosis of Parkinson's Disease Using Multi-Task Learning
inferred← citeshttps://doi.org/10.1159/000480401openalex-snapshot
Exploring the Association between Statin Use and the Risk of Parkinson’s Disease: A Meta-Analysis of Observational Studies
inferred← citeshttps://doi.org/10.1159/000495720openalex-snapshot
Simvastatin Protects Dopaminergic Neurons Against MPP+-Induced Oxidative Stress and Regulates the Endogenous Anti-Oxidant System Through ERK
inferred← citeshttps://doi.org/10.1161/circresaha.119.314929openalex-snapshot
Lipids, Apolipoproteins, and the Risk of Parkinson Disease
inferred← citeshttps://doi.org/10.1161/strokeaha.124.048713openalex-snapshot
Poor Olfaction and Risk of Stroke in Older Adults: The Atherosclerosis Risk in Communities Study
inferred← citeshttps://doi.org/10.1177/2047487318771168openalex-snapshot
Association between physical fitness, cardiovascular risk factors, and Parkinson's disease
inferred← citeshttps://doi.org/10.1186/s13195-023-01326-2openalex-snapshot
Differential effects of cholesterol levels on cognition according to body mass index in Parkinson’s disease
inferred← citeshttps://doi.org/10.1212/wnl.0000000000213931openalex-snapshot
Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia
inferred← citeshttps://doi.org/10.1289/ehp13009openalex-snapshot
Air Pollutants and Risk of Parkinson’s Disease among Women in the Sister Study
inferred← citeshttps://doi.org/10.1371/journal.pone.0138721openalex-snapshot
Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease
inferred← citeshttps://doi.org/10.1371/journal.pone.0152564openalex-snapshot
Statin Use and the Risk of Parkinson's Disease: An Updated Meta-Analysis
inferred← citeshttps://doi.org/10.1371/journal.pone.0175054openalex-snapshot
Statin adherence and the risk of Parkinson's disease: A population-based cohort study
inferred← citeshttps://doi.org/10.1371/journal.pone.0185510openalex-snapshot
Nonmotor symptoms and Parkinson disease in United States farmers and spouses
inferred← citeshttps://doi.org/10.1371/journal.pone.0215246openalex-snapshot
Oxidative stress in lung cancer patients is associated with altered serum markers of lipid metabolism
inferred← citeshttps://doi.org/10.14336/ad.2015.1030openalex-snapshot
Higher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson’s Disease
inferred← citeshttps://doi.org/10.14802/jmd.25008openalex-snapshot
Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson’s Disease
inferred← citeshttps://doi.org/10.1515/revneuro-2022-0093openalex-snapshot
Recent research progress on metabolic syndrome and risk of Parkinson’s disease
inferred← citeshttps://doi.org/10.17116/jnevro20151156261-64openalex-snapshot
Is hyperlipidemia a risk factor of Parkinson’s disease?
inferred← citeshttps://doi.org/10.17756/jnpn.2016-004openalex-snapshot
Associations between 18F-AV133 Cerebral VMAT2 Binding and Plasma LDL and HDL Levels in Parkinson’s Disease
inferred← citeshttps://doi.org/10.20944/preprints202312.2099.v1openalex-snapshot
Assessing the Impact of Multiple Common Factors on the Development of Parkinson’s Disease: An Updated Narrative Review
inferred← citeshttps://doi.org/10.21037/atm.2019.01.68openalex-snapshot
Association between carotid plaque and Parkinson’s disease
inferred← citeshttps://doi.org/10.21569/2222-7415-2018-8-4-23-33openalex-snapshot
THE ROLE OF ULTRASOUND AND LABORATORY METHODS OF STUDYING COMORBID CONDITIONS IN PARKINSON'S DISEASE
inferred← citeshttps://doi.org/10.2174/1570159x15666170703101816openalex-snapshot
Statins and the Brain: More than Lipid Lowering Agents?
inferred← citeshttps://doi.org/10.3233/jpd-150685openalex-snapshot
The Concept of Prodromal Parkinson’s Disease
inferred← citeshttps://doi.org/10.3233/jpd-171203openalex-snapshot
Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress
inferred← citeshttps://doi.org/10.3233/jpd-171238openalex-snapshot
The Changing Landscape of Parkinson Epidemiologic Research
inferred← citeshttps://doi.org/10.3233/jpd-212655openalex-snapshot
Statins in Parkinson’s Disease: Influence on Motor Progression
inferred← citeshttps://doi.org/10.3233/jpd-212670openalex-snapshot
Blood Cholesterol Decreases as Parkinson’s Disease Develops and Progresses
inferred← citeshttps://doi.org/10.3233/jpd-212984openalex-snapshot
Cardiovascular Risk Factors and Phenoconversion to Neurodegenerative Synucleinopathies in Idiopathic REM Sleep Behavior Disorder
inferred← citeshttps://doi.org/10.3233/jpd-230053openalex-snapshot
Parkinson’s Disease Case Ascertainment in the Sister Study: A Cohort for Environmental Health Research
inferred← citeshttps://doi.org/10.3389/fgene.2022.963163openalex-snapshot
Intelligence, education level, and risk of Parkinson’s disease in European populations: A Mendelian randomization study
inferred← citeshttps://doi.org/10.3389/fnagi.2020.00053openalex-snapshot
Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein as Important Markers of Parkinson’s Disease Severity
inferred← citeshttps://doi.org/10.3389/fnagi.2022.797220openalex-snapshot
Altered Cholesterol Homeostasis in Huntington’s Disease
inferred← citeshttps://doi.org/10.3389/fnagi.2024.1388795openalex-snapshot
The causal effects of intelligence and fluid intelligence on Parkinson’s disease: a Mendelian randomization study
inferred← citeshttps://doi.org/10.3389/fneur.2017.00501openalex-snapshot
Circulating Cholesterol Levels May Link to the Factors Influencing Parkinson’s Risk
inferred← citeshttps://doi.org/10.3389/fneur.2020.00597openalex-snapshot
Effects of Higher Serum Lipid Levels on the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3389/fneur.2022.940118openalex-snapshot
Lipid-lowering drug targets and Parkinson's disease: A sex-specific Mendelian randomization study
inferred← citeshttps://doi.org/10.3389/fneur.2023.1236296openalex-snapshot
Mortality and causes of death in patients with Parkinson's disease: a nationwide population-based cohort study
inferred← citeshttps://doi.org/10.3390/cells8010027openalex-snapshot
The Role of Lipids in Parkinson’s Disease
inferred← citeshttps://doi.org/10.3390/ijms222212198openalex-snapshot
A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease
inferred← citeshttps://doi.org/10.3390/ijms23031089openalex-snapshot
Fat and Protein Combat Triggers Immunological Weapons of Innate and Adaptive Immune Systems to Launch Neuroinflammation in Parkinson’s Disease
inferred← citeshttps://doi.org/10.3390/ijms25084358openalex-snapshot
The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
inferred← citeshttps://doi.org/10.3390/jcm15166406openalex-snapshot
Vascular Risk Factors and the Risk of Incident Parkinson’s Disease Among Stroke Survivors: A Nationwide Population-Based Cohort Study
inferred← citeshttps://doi.org/10.3390/jpm12050825openalex-snapshot
Association between Statin Use and Risk of Parkinson’s Disease: Evidence from 18 Observational Studies Comprising 3.7 Million Individuals
inferred← citeshttps://doi.org/10.3390/molecules26102838openalex-snapshot
The Effects of Statins on Neurotransmission and Their Neuroprotective Role in Neurological and Psychiatric Disorders
inferred← citeshttps://doi.org/10.3390/proteomes10010004openalex-snapshot
Potential Tear Biomarkers for the Diagnosis of Parkinson’s Disease—A Pilot Study
inferred← citeshttps://doi.org/10.3390/v11010065openalex-snapshot
Neuroinflammation, Microglia, and Cell-Association during Prion Disease
inferred← citeshttps://doi.org/10.35366/120411openalex-snapshot
Estudio del microsatélite Rep-1 del gen alfa sinucleína en pacientes con la enfermedad de Parkinson idiopática
inferred← citeshttps://doi.org/10.37897/rjn.2023.1.12openalex-snapshot
Correlation of Parkinson’s disease with diabetes mellitus, obesity, dyslipidemia and their association with severity of disease
inferred← citeshttps://doi.org/10.53846/goediss-8016openalex-snapshot
Alpha-synuclein spreading pathology in Parkinson's disease: the influence of iron and the Rho-kinase inhibitor fasudil
inferred← citeshttps://doi.org/10.53846/goediss-8215openalex-snapshot
Der Einfluss von humanem α-Synuclein-Wildtyp und der Mutanten A30P und A53T auf die Autophagie und den Transport synaptischer Vesikel in primären Mittelhirnneuronen der Ratte
inferred← citeshttps://doi.org/10.6084/m9.figshare.25123992openalex-snapshot
Additional file 1 of Differential effects of cholesterol levels on cognition according to body mass index in Parkinson’s disease
inferred← citeshttps://doi.org/10.61958/nmhg9273openalex-snapshot
The network mechanism exploration of Radix Notoginseng for Parkinson's disease through network pharmacology
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.